Pier Capital’s Akero Therapeutics AKRO Stock Holding History

Pier Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-147,841	Closed	-$6.9M	–	119
2023 Q2	$6.9M	Buy	+147,841	New	+$6.78M	0.99%	54

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Pier Capital's AKRO Position: Q3 2023 in Review

Pier Capital sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 147,841 shares — an estimated $6.9M sold.

Pier Capital first reported a position in AKRO in Q2 2023 and held it in 1 quarter. The position peaked at $6.9M in Q2 2023. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

Pier Capital reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
Pier Capital sold 147,841 Akero Therapeutics shares in Q3 2023, an estimated $6.9M.
Pier Capital first reported a position in Akero Therapeutics in Q2 2023 and held it in 1 quarter.
Pier Capital's Akero Therapeutics position peaked at $6.9M in Q2 2023.
181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Pier Capital's 13F filing for Q3 2023, filed 14 Nov 2023.